University of Pennsylvania study for treating the development and severity of atopic dermatitis
The increasing incidence of allergic skin diseases, and the accompanying economic burden and heightened risk of developing other allergic conditions, have spurred researchers to look for better ways to control these immune system-based disorders.
Atopic dermatitis, more commonly called eczema, now affects 10 to 20 percent of children in the United States and direct health-care costs exceed $3 billion, according to the National Institute of Arthritis and Musculoskeletal and Skin Diseases. What’s more, up to 50 percent of children with atopic dermatitis will develop other allergic diseases, including asthma, a phenomenon termed the “allergic march,” the gradual acquisition of co-existing allergic diseases.
David Artis, Ph.D., associate professor of Microbiology, and Brian Kim, M.D., clinical instructor of Dermatology, from the Perelman School of Medicine, University of Pennsylvania, have identified a previously unknown critical role for a recently identified immune cell population in the progression of atopic dermatitis. They describe their findings in the latest issue of Science Translational Medicine. The team found an accumulation of innate lymphoid cells (ILCs) in the active lesions of patients with atopic dermatitis. Using a mouse model of atopic dermatitis they also showed that mouse ILCs contribute to disease progression. These studies suggest ILCs may be a new therapeutic target in treating the development and severity of atopic dermatitis.
“Like foot soldiers protecting the skin barrier from onslaught, innate lymphoid cells are present in healthy skin and we would predict that these cells play a role in maintaining normal tissue function and perhaps in protecting against microbes on this barrier,” says Artis. “However, in chronic inflammatory diseases like atopic dermatitis, unchecked innate lymphoid cell responses can promote inflammation.” Kim adds, “A potential consequence of our more hygienic environment is that immune cells may be left somewhat redundant and so contribute to the increasing incidence of allergic diseases like eczema.”
Many studies before the current one in STM have identified immune pathways that activate ILCs in such other tissues as the intestine and lung. “An unexpected finding of the current study is that innate lymphoid cells in the skin appear to be activated and regulated by different pathways,” says Kim. “These findings suggest that tissue-specific local signals may regulate their function. This finding may also offer therapeutic potential to selectively target innate lymphoid cells in certain tissues, especially for limiting disease severity.”
At present, the first-line therapy for atopic dermatitis remains topical steroids. Unlike other inflammatory diseases like psoriasis and arthritis that can be treated with modern biologic-based therapies, there are no targeted biologic therapies that are approved for use to treat atopic dermatitis.
“Our findings give us hope that new biologic therapies may be designed to treat atopic dermatitis in the future,” says Artis.
These studies are part of a new collaboration between basic scientists in Penn’s Department of Microbiology and Institute for Immunology, along with clinicians at Penn’s Department of Dermatology. These studies are supported by the National Institutes of Health’s Clinical and Translational Science Award program, which is administered through Penn’s Institute for Translational Medicine and Therapeutics.
Research in the Artis lab is supported by the National Institutes of Health (AI061570, AI087990, AI074878, AI083480, AI095466, AI095608, AI097333, AI102942) and the Burroughs Wellcome Fund Investigator in Pathogenesis of Infectious Disease Award.
Kim is funded by NIH grant KL2-RR024132. The study was also funded by the Swiss National Science Foundation Prospective Research Fellowship, the NCI Comprehensive Cancer Center Support Grant (2-P30 CA016520); the NIH/NIDDK P30 Center for Molecular Studies in Digestive and Liver Diseases (P30-DK050306), the National Center for Research Resources and the National Center for Advancing Translational Sciences (KL2TR000139), and the Skin Disease Research Center (SDRC 5-P30-AR-057217).
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania — recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital — the nation’s first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.